Medicus Pharma Ltd
MDCX1.110USD
+0.020+1.83%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
23.28MMarket Cap
LossP/E TTM
More Details of Medicus Pharma Ltd Company
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Medicus Pharma Ltd Info
Ticker SymbolMDCX
Company nameMedicus Pharma Ltd
IPO dateOct 11, 2023
CEOBokhari (Raza)
Number of employees12
Security typeOrdinary Share
Fiscal year-endOct 11
Address300 Conshohocken State Rd.
CityCONSHOHOCKEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19428
Phone16105407515
Websitehttps://medicuspharma.com/
Ticker SymbolMDCX
IPO dateOct 11, 2023
CEOBokhari (Raza)
Company Executives of Medicus Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F. Bonner
Ms. Carolyn F. Bonner
President, Chief Financial Officer
President, Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Edward J. Brennan, Jr., M.D.
Dr. Edward J. Brennan, Jr., M.D.
Chief Scientific Officer, Head of Research and Development Program
Chief Scientific Officer, Head of Research and Development Program
--
--
Dr. Larry R. Kaiser
Dr. Larry R. Kaiser
Independent Director
Independent Director
--
--
Mr. Robert J. Ciaruffoli, CPA
Mr. Robert J. Ciaruffoli, CPA
Lead Independent Director
Lead Independent Director
--
--
Mr. Frank W. Lavelle
Mr. Frank W. Lavelle
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Raza Bokhari, M.D.
Dr. Raza Bokhari, M.D.
Executive Chairman, of the Board, Chief Executive Officer
Executive Chairman, of the Board, Chief Executive Officer
793.17K
--
Mr. Patrick J. Mahaffy
Mr. Patrick J. Mahaffy
Director
Director
35.44K
--
Ms. Carolyn F. Bonner
Ms. Carolyn F. Bonner
President, Chief Financial Officer
President, Chief Financial Officer
18.91K
--
Mr. William L. (Bill) Ashton
Mr. William L. (Bill) Ashton
Independent Director
Independent Director
1.25K
--
Mr. Andrew A. Smith
Mr. Andrew A. Smith
Chief Operating Officer
Chief Operating Officer
164.00
--
Dr. Faisal Mehmud, M.D.
Dr. Faisal Mehmud, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Velocity Fund Partners LP
11.31%
215 Capital Togo PHL Fund I, LP
7.96%
Interchange Capital Partners LLC
6.32%
Hathaway (John)
3.19%
Bokhari (Raza)
3.16%
Other
68.06%
Shareholders
Shareholders
Proportion
Velocity Fund Partners LP
11.31%
215 Capital Togo PHL Fund I, LP
7.96%
Interchange Capital Partners LLC
6.32%
Hathaway (John)
3.19%
Bokhari (Raza)
3.16%
Other
68.06%
Shareholder Types
Shareholders
Proportion
Corporation
19.27%
Individual Investor
9.69%
Investment Advisor
7.46%
Investment Advisor/Hedge Fund
0.94%
Bank and Trust
0.10%
Other
62.55%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
2.12M
8.43%
-1.40M
2025Q3
28
2.07M
9.63%
-1.12M
2025Q2
22
10.21M
64.09%
+108.37K
2025Q1
19
10.07M
84.39%
+1.61M
2024Q4
12
8.43M
77.76%
+1.48M
2024Q3
8
6.05M
68.59%
+2.33M
2024Q2
7
4.05M
50.15%
+329.10K
2024Q1
9
3.82M
47.35%
+3.82M
2023Q4
9
3.82M
47.35%
+3.82M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Velocity Fund Partners LP
2.84M
11.31%
--
--
Nov 07, 2025
215 Capital Togo PHL Fund I, LP
2.00M
7.96%
--
--
Nov 07, 2025
Interchange Capital Partners LLC
1.59M
6.32%
--
--
Sep 30, 2025
Hathaway (John)
800.95K
3.19%
--
--
Jun 30, 2025
Bokhari (Raza)
793.17K
3.16%
--
--
Dec 31, 2025
Melani (Kenneth)
409.41K
1.63%
--
--
Nov 07, 2025
Quinlan (James P)
274.15K
1.09%
--
--
Nov 07, 2025
Yorkville Advisors Global, LP.
230.00K
0.92%
+124.16K
+117.31%
Sep 30, 2025
Private Advisor Group LLC
151.50K
0.6%
+5.50K
+3.77%
Sep 30, 2025
Brennan (Edward Joseph JR)
86.50K
0.34%
--
--
Nov 07, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
